MNPR
Monopar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$96.47
−6.07%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$103.96
From 52W high−22.10%
Volume379310.00
Market cap$647.52M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$103.96
From 52W high
−22.10%
Volume
379310.00
Market cap
$647.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−27.7x
P/E (TTM)
—
RSI (14)
33.0
MomentumView details →
1D Return
−6.07%
YTD Return
+48.66%
SummaryUpdated Jun 1, 2026
Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Wilmette, Illinois. The company went public in December 2019 and focuses on developing innovative therapeutic treatments for cancer patients. As a clinical-stage biotechnology firm, Monopar does not yet generate revenue from product sales but instead operates through research and development activities funded by investor capital and potential partnerships.
Similar companies
Latest newsMore news →
Kim R. Tsuchimoto, a director at Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026, for a total value of $455,566, and exercised options to acquire the same number of shares on the same day.23d agoMonopar Therapeutics reported a net loss of $5.3 million, or $0.62 per share, for Q2 2026, compared to a net loss of $2.5 million, or $0.35 per share, in Q2 2025.40d ago